CVRARTR

CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research[1][2].

Product Specifications

CAS Number

[2349354-64-7]

UNSPSC

12352209

Target

PD-1/PD-L1

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cvrartr.html

Purity

99.26

Solubility

DMSO : 6.25 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](CS)N

Molecular Formula

C33H64N16O9S

Molecular Weight

861.03

References & Citations

[1]Gurung S, et al., Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression. Biomaterials. 2020 Jul;247:119984. |[2]Moon Y, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022 Jan 31;12 (5) :1999-2014.